News|Articles|October 27, 2026

Stress and Mood Ingredients in 2026: New Data, New Entrants, and Regulatory Signals

Author(s)Erin McEvoy

A roundup of recent adaptogen trials, newer botanical and fermentation-derived ingredients, and approvals in Canada and South Korea, with a look at the limits of the evidence for manufacturers.

Stress and mood remain among the most active areas of botanical innovation, with recent coverage pointing to new clinical data on established adaptogens, regulatory recognition abroad, and newer ingredients entering the field. This roundup summarizes stress- and mood-related findings from Nutritional Outlook’s coverage since the start of 2026, with a focus on what they mean for supplement manufacturers.

Related to this article

Elzaphan Hotam
Live from SupplySide Global 2026, Nutritional Outlook’s Nicholas Jacobus speaks with Elzaphan Hotam, director at TriNutra, about new clinical and preprint data on ThymoQuin.